Corcept Therapeutics Incorporated
CORT
Rang in Aktien
#1814
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Aktienkurs
$109.25
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$11.81B
Veränderung (1 Tag)
-3.64%
Veränderung (1 Jahr)
38.83%
Land
US
Handel Corcept Therapeutics Incorporated (CORT)
Kategorie
Healthcare
EPS für Corcept Therapeutics Incorporated (CORT)
EPS zum June 2026 TTM: $0.52
Laut den aktuellen Finanzberichten und dem Aktienkurs von Corcept Therapeutics Incorporated beträgt das aktuelle EPS des Unternehmens (TTM) $0.52. Am Ende des Jahres 2023 betrug das EPS $1.02 eine Steigerung gegenüber dem EPS von 2022, das $0.95 betrug.
EPS-Verlauf von Corcept Therapeutics Incorporated von 2001 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $0.52 | -61.48% |
| 2024 | $1.35 | 32.35% |
| 2023 | $1.02 | 7.37% |
| 2022 | $0.95 | -2.06% |
| 2021 | $0.97 | 5.43% |
| 2020 | $0.92 | 12.20% |
| 2019 | $0.82 | 36.67% |
| 2018 | $0.60 | -47.37% |
| 2017 | $1.14 | 1,528.57% |
| 2016 | $0.07 | -216.67% |
| 2015 | $-0.06 | -80.65% |
| 2014 | $-0.31 | -32.61% |
| 2013 | $-0.46 | 12.20% |
| 2012 | $-0.41 | 5.13% |
| 2011 | $-0.39 | 2.63% |
| 2010 | $-0.38 | 0.00% |
| 2009 | $-0.38 | -11.63% |
| 2008 | $-0.43 | 26.47% |
| 2007 | $-0.34 | -68.81% |
| 2006 | $-1.09 | 22.47% |
| 2005 | $-0.89 | 5.95% |
| 2004 | $-0.84 | -25.66% |
| 2003 | $-1.13 | -58.91% |
| 2002 | $-2.75 | 97.84% |
| 2001 | $-1.39 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $2.41 | 363.46% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.02 | -96.38% |
HK
|
